Advances in Systemic Amyloidosis: A Spotlight on New Disease-Modifying Therapies Across the Clinical Spectrum

Download All
Explore recent advances in amyloidosis treatment and management with an expert-authored interactive actvity, a commentary, and a downloadable slideset.
Raymond L. Comenzo, MD

ClinicalThought Commentary

The approval of the anti-CD38 antibody daratumumab has provided a valuable new option for patients with light-chain amyloidosis. Review this expert commentary to get a top-level view of this disease and current best practices.

Raymond L. Comenzo, MD Released: August 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue